라이프
전체기사 보기-
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended December 31, 2025. FY 2025 key results1 Group performance2: Double-digit revenue growth and positive adjusted operating cash flow Revenue of US$803.8 million, up by 56%3 and achieving upsized full year guidance4. US$157.1 million invested in research and development (R&D) product development for late-stage therapeutics and precision medicine pipeline assets5,
- 김갑성 기자
- 2026-02-20 07:27
-
Indian, Regional, and Global Partners Launch Initiatives to Address Extreme Heat in South Asia
[ 메디채널 김갑성 기자 ] The World Health Organization (WHO)–World Meteorological Organization (WMO) Climate and Health Joint Programme, The Rockefeller Foundation, and Wellcome announce new regional efforts to connect climate science to health action to prevent heat impacts, help communities flourish, and save lives. MUMBAI, India, Feb. 20, 2026 -- At Mumbai Climate Week, the WHO-WMO Climate and Health Joint Programme, The Rockefeller Foundation, and Wellcome announced two new integrated initiatives to protect South Asians from extreme heat – a rapidly escalating threat to human health and e
- 김갑성 기자
- 2026-02-20 04:56
-
TraceLink Named to RXinsider's 2026 Pharmacy500 for Powering Digital Network Orchestration Across the Regulated Pharmacy Supply Chain
The recognition highlights TraceLink's Business-to-Network Integrate-Once™ platform that enables end-to-end digitalization, interoperable compliance execution, and operational resilience at industry scale Summary TraceLink is recognized for delivering a unified, network-based platform that helps pharmacies and their trading partners orchestrate procure-to-pay through an Integrate-Once™ model, automate the identification and reconciliation of recalled products, and operationalize DSCSA regulatory requirements on an industrial-grade foundation designed for mission-critical, regula
- 김갑성 기자
- 2026-02-19 23:00
-
BON Announces Breakthrough Development of Apple Bio-Electronic Mask: Clinical Data Exceeds Expectations, Targeting $100B+ Medical Aesthetics Market
XI'AN, China, Feb. 19, 2026 -- Bon Natural Life Limited (Nasdaq: BON) ("Bon" or the "Company"), a leading provider of bio-ingredient solutions in the natural, health, and personal care industries, today announced the successful development of a premium anti-aging facial mask incorporating apple polyphenols as its core active ingredient and integrated with AI-enabled flexible bio-electronic technology. Leveraging advanced transdermal delivery systems, this product integrates plant-derived active ingredients with intelligent flexible electronics, creating a next-generation s
- 김갑성 기자
- 2026-02-19 22:00
-
3Shape Boosts Dental Lab Speed and Accuracy with AI-Powered Workflows
COPENHAGEN, Denmark, Feb. 19, 2026 -- At LMT LabDay today, 3Shape showcases its AI-powered and integrated workflows that help dental labs work faster, reduce errors, and handle more cases efficiently. A reliable bite setup in seconds Scans from intraoral scanners can sometimes include missing or inaccurate bite data. To save them time and eliminate their need for manual adjustment of missing jaw relationship data, 3Shape Dental System 2025 has introduced AI-bite alignment. The AI bite alignment tool analyzes dental arches in the scans and places them in a static occlusion
- 김갑성 기자
- 2026-02-19 21:07
-
Cambrex Announces Cornell Professor Song Lin as Recipient of the 2025 Snapdragon Prize for Innovation in Chemistry Technology
EAST RUTHERFORD, N.J., Feb. 19, 2026 -- Cambrex, a leading global contract development and manufacturing organization (CDMO) and Snapdragon Chemistry, a Cambrex company, are proud to announce that Dr. Song Lin, Tisch University Professor in chemistry and chemical biology at Cornell University's College of Arts and Sciences, has been awarded the 2025 Snapdragon Prize for Innovation in Chemistry Technology, which includes a $50,000 unrestricted fund for the Lin Lab. Professor Lin is being honored for his pioneering research in electrosynthetic chemistry, which has opened
- 김갑성 기자
- 2026-02-19 19:00
-
캠브렉스, 2025년 스냅드래곤 화학 기술 혁신상 수상자로 코넬대 송린 교수 선정
이스트러더퍼드, 뉴저지, 2026년 2월 19일 -- 글로벌 선도 의약품 위탁개발생산기업(contract development and manufacturing organization, CDMO)인 캠브렉스(Cambrex)와 캠브렉스 계열사인 스냅드래곤 케미스트리(Snapdragon Chemistry)가, 코넬대학교 예술과학대학의 화학 및 화학생물학과의 송린(Song Lin) 티시 석좌교수가 2025년 스냅드래곤 화학 기술 혁신상(2025 Snapdragon Prize for Innovation in Chemistry Technology) 수상자로 선정됐다고 발표했으며, 수상에는 린 연구실(Lin Lab)에 지원되는 미화 5만 달러의 무제한 연구 기금이 포함된다. 린 교수는 전기 합성 화학 분야의 선구적 연구로 수상의 영예를 안았으며, 그의 연구는 전기화학을 의약품 개발 및 제조에 활용하는 새로운 길을 열었다는 평가를 받는다. 린 교수의 연구실은 유기화학, 전기 합성, 촉매, 기술 개발 분야의 발전에 주력하고 있다. 특히 의약품 혁신에 핵심적인 카이랄 화합물을 포함한 복잡한 유기 분자의
- 김갑성 기자
- 2026-02-19 19:00
-
FDA, 치명적 약제내성 병원체 표적 신속 검사 2종을 혁신 의료기기로 지정
산타마리아, 캘리포니아 및 기프리, 프랑스 , 2026년 2월 19일 -- 엔지 바이오텍(NG Biotech)과 하디 다이애그노스틱스(Hardy Diagnostics)가 항생제 내성(Antimicrobial Resistance, AMR)에 대응하는 중대한 진전을 이룬 가운데 미국 식품의약국(Food and Drug Administration, FDA)에서 두 가지 신속 진단 분석법 NG-TEST®Candida auris와 NG-TEST®Acineto-5®을 혁신 의료기기로 지정했다고 2월 18일 발표했다. 이 지정은 생명을 위협하는 질환 및 중대한 미충족 의료 수요를 해결할 잠재력을 지닌 기술을 대상으로 하는 것이다. 두 검사는 모두 세계보건기구(World Health Organization, WHO)에서 최우선으로 분류한 병원체가 대상이다. 칸디다 아우리스(Candida auris)는 WHO 진균 우선순위 병원체 목록(Fungal Priority Pathogens List 2022)에 등재된 다제내성 효모로, 전 세계 병원 내 집단감염의 원인이 되고 있으며 검출이 어렵고 높은 사망률과 연관이 있다. 카바페
- 김갑성 기자
- 2026-02-19 10:31
-
A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants
Japan's Ministry of Health, Labour and Welfare (MHLW) Approves PreemieFort® Enteral Solution as Prescription Medicine in the NICU DUARTE, Calif., Feb. 19, 2026 -- Prolacta Bioscience® today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved PreemieFort® Enteral Solution, a 100% human milk-based fortifier, as a prescription drug for very low birth weight infants, infants with congenital gastrointestinal disorders or congenital heart diseases, and those recovering from gastrointestinal surgery. This regulatory milestone was achieved in
- 김갑성 기자
- 2026-02-19 05:03
-
Lifespan Vision Ventures Co-Leads Sift Biosciences' $3.7M Pre-Seed Financing
NORWALK, Conn., Feb. 19, 2026 -- Lifespan Vision Ventures, an investment firm focused on therapeutics that improve human healthspan, today announced that it has co-led Sift Biosciences' oversubscribed $3.7 million Pre-Seed financing alongside Freeflow Ventures, with participation from Valuence Ventures, Eisai Innovation, SBI US Gateway Fund, and other early investors. Sift Biosciences is developing a peptide-based immunotherapy platform designed to harness pre-existing immune memory. The company's approach aims to generate more consistent immune engagement by activating memory
- 김갑성 기자
- 2026-02-19 01:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 7만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2026-02-21_SAT
2026-02-20_FRI
- NYSE Content Update: Starfighters Space Celebrates NYSE American Listing 22:28
- MD Local Global Announces Strategic Cultural Partnership with H5 for Fernie Castle Animation Art Gallery 22:05
- HeyGears Announces One-Piece Denture Solution - Redefining Digital Dentures with Dual-Material 3D Printing 22:00
- LanzaJetが4700万ドルの新規資金を確保し、プレマネー評価額6億5000万ドルでエクイティ投資ラウンドの初回クローズを完了、SAF技術の有効性をさらに実証し今後の成長を加速 18:11
- 今年は午年、どんな抱負を持ちますか？在広州の各国総領事からのメッセージをご覧ください 17:53
- Yiwu Invites Global Guests to a "Spring Festival Gala Style" New Year 16:57
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2026년 02월 21일 06시 40분